Association of Visfatin with Blood Glucose, Insulin Resistance and Body Mass Index in Patients with Type 2 Diabetes/Pre-Diabetes

H Karimi; M Nezhadali; M Mahdavi; M Saatian; L Saeedi

doi:10.18502/jabs.v11i3.8792

H Karimi Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Science, Shahid Beheshti University of Medical Science, Tehran Iran
M Nezhadali Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran
M Mahdavi Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
M Saatian Department of Pathology, Islamic Azad University, Medical Tehran Branch, Tehran, Iran
L Saeedi Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran

DOI: https://doi.org/10.18502/jabs.v11i3.8792

Keywords: Type 2 diabetes, visfatin, insulin resistance, body mass index, fasting blood glucose

Abstract

Background & Objective: In recent studies visfatin plays a role in pathogenesis of many disorders such as obesity and type 2 diabetes. The aim of this study was to evaluate the association of visfatin with fasting blood glucose, insulin resistance and body mass index in patients with type 2 diabetes/ impaired fasting glucose (IFG) compared to non-diabetic subjects.

Material & Methods: This case control study was performed on 160 volunteers. 80 participants were categorized in type 2 diabetic group holding FBG ≥100 (mg/dl) and 80 participants were categorized in non-diabetic group holding FBG 70-100 (mg/dl). Serum visfatin and insulin levels were measured using enzyme-linked immunosorbent assay.

Results: The result was presented as mean± standard deviation and p<0.05 was considered as statistically significant. Diabetic group showed a higher level of age in comparison with the non-diabetics. Meanwhile, the means of TG, FBG, BMI, WC, HC and HOMA were also significantly different between the two groups. Visfatin level was not different between diabetics and normal healthy controls. There was a positive correlation between visfatin and BMI in non-diabetics. Also, in diabetics there was a positive correlation between visfatin and BMI, HDL, Hip, insulin and HOMA-IR and a negative correlation with FBG.

Conclusion: Our study showed an association between visfatin and BMI but not with type 2 diabetes. Also, there was a significant association between this adipokine and insulin resistance in diabetic and pre-diabetic patients which indicates the pathological role of visfatin in insulin resistance.